Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Zoledronic acid (ZOL), a third-generation aminobisphosphonate, showed pronounced antifracture efficacy in a phase III clinical trial [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly—Pivotal Fracture Trial (HORIZON-PFT)] when administered yearly (5-mg infusions of ZOL), producing significant reductions in morphometric vertebral, clinical vertebral, hip, and nonvertebral fractures by 70%, 77%, 41%, and 25%, respectively, over a 3-year period. The purpose of this study was to analyze the biopsies obtained during the HORIZON clinical trial (152 patients, 82 ZOL and 70 placebo) by means of Raman microspectroscopy (a vibrational spectroscopic technique capable of analyzing undecalcified bone tissue with a spatial resolution of approximately 0.6 µm) to determine the effect of ZOL therapy on bone material properties (in particular mineral/matrix ratio, lamellar organization, carbonate and proteoglycan (based on spectral identification of glycosaminoglycan) content, and mineral maturity/crystallinity) at similar tissue age (based on the presence of tetracycline double labels). The results indicated that while ZOL administration increased the mineral/matrix ratio compared with placebo, it also resulted in mineral crystallites with a quality profile (based on carbonate content and maturity/crystallinity characteristics) of younger (with respect to tissue age) bone. Since the comparisons between ZOL- and placebo-treated patients were performed at similar tissue age at actively forming bone surfaces, these results suggest that ZOL may be exerting an effect on bone matrix formation in addition to its well-established antiresorptive effect, thereby contributing to its antifracture efficacy. © 2011 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 1×
“The phase III Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly—Pivotal Fracture Trial (HORIZON-PFT) enrolled 7736 postmenopausal women with osteoporosis and showed pronounced antifracture efficacy of yearly 5-mg infusions of ZOL with significant reductions of morphometric vertebral, clinical vert…”
BackgroundSelf-citationNancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H. (2006) · Bone · doi:10.1016/j.bone.2005.05.003 · Cited by 862 · cited 1×
“A potential explanation may lie in the reported properties of apatite following bisphosphonate adsorption.((34,35)) Among bisphosphonates currently used as osteoporosis therapies, ZOL not only has the highest affinity for apatite crystals but also is the only agent that exhibits a negative zeta potential once adsorbed…”
BackgroundMisof, B. M., Bodingbauer, M., Roschger, P., Wekerle, T., Pakrah, B., Haas, M., Kainz, A., Oberbauer, R., Mühlbacher, F., & Klaushofer, K. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9161-2 · Cited by 41 · cited 2×
“Its utility in preventing bone loss also has been shown in the case of posttransplant osteoporosis after liver and renal transplantation.((6,7)) The phase III Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly—Pivotal Fracture Trial (HORIZON-PFT) enrolled 7736 postmenopausal women with osteoporosis…”
BackgroundResultSelf-citation
Cited by
Bone composition: relationship to bone fragility and antiosteoporotic drug effects
Boskey, A. L. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.181 · Cited by 424
Mirzaali, M. J., Schwiedrzik, J. J., Thaiwichai, S., Best, J. P., Michler, J., Zysset, P. K., & Wolfram, U. (2016) · Bone · doi:10.1016/j.bone.2015.11.018 · Cited by 325
“254 Following Akkus et al. (2004), Yerramshetty et al. (2006), Morris and Mandair255 (2011), Gamsjaeger et al. (2011), and Gamsjaeger et al. (2014) (and references256 therein), we analysed the ratio of the integrated areas of the v1PO4 (900 – 1000 cm -1)257 to the amide I (1620 – 1720 cm-1) band to…”
BackgroundMethodResultInfluentialAdvanced Glycation Endproducts and Bone Material Properties in Type 1 Diabetic Mice
Rubin, M. R., Paschalis, E. P., Poundarik, A., Sroga, G. E., McMahon, D. J., Gamsjaeger, S., Klaushofer, K., & Vashishth, D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154700 · Cited by 90
“Once acquired, the Raman spectra were baseline corrected (rubber band, 5 iterations) to account for fluorescence, and the following Raman variables were calculated as published elsewhere [15].”
Self-citation
Metadata
- Authors
- Gamsjaeger, S., Buchinger, B., Zwettler, E., Recker, R., Black, D., Gasser, J. A., Eriksen, E. F., Klaushofer, K., & Paschalis, E. P.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-12-22
- Volume
- 26
- Issue
- 1
- Pages
- 12-18
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2009597432
- Cited by
- 94
- References
- 3
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.